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SHORT COMMUNICATION
Exceptional sensitivity of testicular germ cell tumour cell lines to the new
anti-cancer agent, temozolomide
MF Peral, B K6berle2 and JRW Masters2
'CRC Growth Factors, Department ofZoology, Oxford University, South Parks Road, Oxford OX] 3PS, UK; 2lnstitute of
Urology and Nephrology, University College London, 3rd Floor Research Laboratories, 67 Riding House Street, London
WIP 7PN, UK.
S_ry Metastatic testicular germ cell tumours are cured in approximately 85% of patients using cisplatin-
based combination chemotherapy. Patients who fail to respond have a poor prognosis, and there is a need for
more effective treatments for cisplatin-resistant disease. In this study, it is shown that two of four cell lines
derived from human non-seminomatous testicular germ cell tumours are exceptionally sensitive to
temozolomide, a new imidazotetrazne which can cross the blood-brain barrier in mice. In addition, three
pairs of cisplatin-resistant sublines show little cross-resistance to temozolomide. These data suggest that
temozolomide might have activity against non-seminomatous testicular germ cell tumours which have relapsed
following cisplatin-containing chemotherapy, and could have a role in the treatment of patients with metas-
tatic lesions in the brain.
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Despite the high cure rate obtained with combination chemo-
therapy of non-seminomatous testicular germ cell tumours,
the management of patients with an adverse prognosis at
presentation, or of those who fail to respond to first-line
chemotherapy, remains a therapeutic challenge (Horwich et
al., 1993). Most experimental protocols aimed at these poor-
risk groups, which constitute about 15% of the patient
population, involve intensification of chemotherapy with
agents already known to be active against the disease. It may
be that the addition to these regimens of a new drug with a
different molecular mechanism of action would have a
positive impact on the outcome of treatment.
Cell lines derived from human non-seminomatous testicu-
lar germ cell tumours are highly sensitive to cisplatin (Pera et
al., 1987a; Walker et al., 1987). The pattern of sensitivity
observed in vitro appears to reflect the cliical response, as
testis tumour cells are 3-10 times more sensitive to isplatin,
bleomycin and etoposide than bladder cancer cells, compar-
ing IC50 values (Masters et al., 1993). These cell lines are also
highly sensitive to another class of DNA-damaging agent:
compounds which can alkylate the o6 position of guanine
(Walker et al., 1992). The mutagenic consequences of 06
alkylation of guanine are well described. In addition, some
mammalian cells are acutely sensitive to the cytotoxic effects
of compounds which generate this lesion (reviewed in
Roberts, 1978).
Temozolomide, which undergoes chemical decomposition
to yield a monofunctional alkylating agent capable of bind-
ing to the 06 position of guanine, is a new anti-cancer agent
which is less toxic than mitozolomide (Newlands et al., 1992)
and which has the ability to cross the blood-brain barrier in
mice. We compared the sensitivities to temozolomide of a
series of human bladder and testicular germ cell tumour cell
lines and three pairs of parent and cisplatin-resistant sub-
lines.
MateriaL and nthods
The origins of the cell lines used in this study are shown in
Table I. All cell lines were maintained routinely under iden-
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tical conditions as monolayers in 25 cm2 tissue culture flasks
(Nunc, Gibco, Paisley, UK) using alpha minimum essential
tissue culture medium (aMEM) supplemented with a single
batch of 5% heat-inactivated fetal calf serum (Imperial Labs)
and 2 mM L-glutamine (Flow, Irvine, UK) in a humidified
atmosphere of 5% carbon dioxide in air at 36.5C. The cells
were used over a restricted range of ten passages to minimise
changes that might occur dunrng long-term culture.
Clonogenic assay
Exponentially growing cells were detached using 0.05% tryp-
sin (Difco 1:250; Difco, London, UK) in an aqueous solu-
tion of0.016% ethylenediamine tetraacetic acid disodium salt
(EDTA; BDH Chemicals, Poole, UK) and were plated in
5 cm dishes containing 5 ml of prewarmed and gassed
medium at a plating density designed to produce approx-
imately 200 colonies per plate in the untreated controls.
Following a 24 h incubation to permit attachment and the
resumption of exponential growth, the medium was replaced
either with fresh medium alone (in quintuplicate) or contain-
ing 0.5% dimethyl sulphoxide (DMSO; Sigma, Poole, UK)
or a range of temozolomide (Aston Molecules, UK) concent-
rations (in triplicate for each concentration).Temozolomide
was dissolved in DMSO and the stock solution subsequently
added to culture medium. The final volume of DMSO did
not exceed 0.5%, a non-toxic concentration. Preliminary
experiments identified the range of cytotoxic concentrations,
and at least three concentrations which fell in the exponential
region of the dose-response curve were selected. After a
further 9-15 days' culture, colonies were fixed in methanol
(BDH) and stained with 10% Giemsa (BDH). Colonies con-
taining a minimum of 50 cells were counted using a binocular
dissecting microscope. The mean colony-forming ability was
expressed as a percentage of the untreated controls and
computed using least-squares regression analysis on the
straight portion of the dose-response plot. The drug was
tested against each cell line in at least two further
experiments.
Results
The toxicity of temozolomide to four testis tumour and three
bladder cancer cell lines was measured (Figure la). Two ofTemnuuloui*e sAdity d tm*cw germ cd bmis
MF Pera etal 0
905
Table I Origins and characteristics of the cell lines used in this study
Cell line Previous ATase level Temozolomide mean
designation Histopathological tpe treatment (fmolmg-' protein) IC5o (tgm.l-') References
SuSa NSTGCI primary None 206 23.2 Hogan et al. (1977)
SuSa-CP Cisplatin-resistant subline 470 50.5 Walker et al. (1990)
833K NSTGCT (abdominal metastasis) Chemotherapyb ND 27.6 Bronson et al. (1980)
GCT27 NSTGCT primary None 3.3 0.54 Pera et al. (1987b)
GCT27-CP Cisplatin-resistant subline ND 0.72 Kelland et al. (1992)
GCT44 NSTGCT (lymph node metastasis) Chemotherapy' ND 5.8 Pera et al. (1987b)
RT112 TCC primary None 387 24.2 Masters et al. (1986)
RT112-CP Cisplatin-resistant subline 301 45.9 Walker et al. (1990)
MGH-Ul (T24) TCC recurrence None 603 24.5 Bubenik et al. (1973)
HT1376 TCC primary None 506 30.3 Rasheed et al. (1977)
NSTGCT, non-seminomatous testicular germ cell tourm TCC, transitional cell carcinoma of the bladder, ND, not done. 'From Walker et
al. (1992). bMethotrexate, actinomycin D, cyclophosphamide. 'Cisplatin, etoposide, bleomycin, vinblastine, methotrexate, doxorubicin,
actinomycin D, cyclophosphamide.
the four testis tumour lines, GCT27 and GCT44, were far
more sensitive to temozolomide than the other cell lines.
GCT27 was derived from a primary tumour in a patient who
had not been treated with chemotherapy. In contrast, GCIT44
was derived from a metastatic lesion in a patient who had
previously been treated and subsequently died of his disease.
GCT44 represents an aggressive biological variant of tera-
toma (Pera et al., 1987b). Comparing the temozolomide sen-
sitivity of three of these lines with their cisplatin-resistant
sublines, the relative cross-resistance to temozolomide ranged
from 1.3 for GCT27 to 2.2 for SuSa (Figure lb and Table I),
comparing the mean concentrations reducing colony-forming
ability by 50% (ICv). The sublines were derived by con-
tinuous in vitro exposure to cisplatin, and exhibit a 4- to
6-fold resitance to cisplatin, comparing doses that reduce
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Fugwe 1 Dose -response curves of testis and bladder cancer cell
lines to temozolomide. Cells plated at clonal density were exposed
to a range of concentrations of temozolomide, and after a further
9-15 days' culture the colony-forming ability of the treated cells
was compared with that of the untreated controls. (a) Data for
four testis: (0, GCT44; A, SuSa; *, 833K; *, GCT27) and
three bladder (0, RT1 12; A, MGH-U1; 0, HT1376) cancer cell
lines. (b) Data for three pairs of parent (A, SuSa; *, GCT27; 0,
RTI 12) and cisplatin-resistant sublines (A, SuSa-CP; O, GCT27-
CP; 0, Ri 12-CP). Survival for each drug dose was estimated
from triplicate dishes, and each experiment was repeated at least
twice. The error bars show the standard error of the-mean of the
separate experiments.
Two testis tumour cell lines were shown to be exceptionally
sensitive to temozolomide. This fmding eitends our observa-
tion that testis tumour cell lines are particuly sensitive to
N-nitroso-N-methylurea (MNU) and mitozolomide (Walker
et al., 1992). This earlier study also demonstrated that
GCT27 is more sensitive than the other testis tumour lines
studied, with IC50 values to MNU and mitozolomide of 1.2
and 0.31ggmlP', compared with 12.2 and 1.3jLgml-' for
SuSa (testis) and 56.9 and 4.5JLgml-' for RT112 (bladder).
The greater sensitivity of GCT27 to temozolomide, mitozolo-
mide and MNU may be related to its low levels of o6-
alkylguanine-DNA alkyltransferase activity (see Table I).
Low levels of this enzyme may result in higher levels of 06
alkylation, a potentially toxic DNA lesion.
The exceptional sensitivity of the two testis lines to temo-
zolomide is one reason for testing this new drug in the clinic
against testis tumours. The major limitation to the successful
treatment of these patients is the presence of cisplatin-
resistant disease. Therefore, a further rationale for testing
this new agent is the observation that in three independent
pairs of cell lines there is relatively little change in the
sensitivity to temozolomide in the cisplatin-resistant deriv-
atives. A third reason for testing this agent is its clinical
activity against brain tumours (Newlands et al., 1992). Brain
metastases occur in 8-15% of patients with testicular
tumours, almost always associated with relapse at other sites
or as a terminal event (Raina et al., 1993). Temozolomide
may provide a more effective treatment for testis tumours
which have metastasised to the brain.
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